Literature DB >> 20954291

Haemodynamic and renal effects of tadalafil in patients with cirrhosis.

Georgios N Kalambokis, Paraskevi Kosta, Konstantinos Pappas, Epameinondas V Tsianos.   

Abstract

A recent report introduced the phosphodiesterase-5 inhibition by vardenafil as a novel treatment of portal hypertension in patients with cirrhosis. In the herein presented "letter to the editor", the administration of tadalafil did not influence portal haemodynamics but impaired systemic haemodynamics in patients with cirrhosis. Our observations concur with the results of a report in a previous issue of World Journal of Gastroenterology (October 2008). Moreover, tadalafil adversely affected renal function in patients with decompensated liver disease.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20954291      PMCID： PMC2957613          DOI： 10.3748/wjg.v16.i39.5009

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  6 in total

1.  Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.

Authors:  P Deibert; Y-O Schumacher; G Ruecker; O G Opitz; H E Blum; M Rössle; W Kreisel
Journal:  Aliment Pharmacol Ther       Date:  2006-01-01       Impact factor: 8.171

2.  Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.

Authors:  Helle C Thiesson; Boye L Jensen; Bente Jespersen; Ove B Schaffalitzky de Muckadell; Claus Bistrup; Steen Walter; Peter D Ottosen; Annegrete Veje; Ole Skøtt
Journal:  Am J Physiol Renal Physiol       Date:  2004-12-21

3.  Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis.

Authors:  Puneeta Tandon; Irteza Inayat; Michael Tal; Marcelo Spector; Martha Shea; Roberto J Groszmann; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-06       Impact factor: 11.382

4.  Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.

Authors:  Jens-Otto Clemmesen; Annamaria Giraldi; Peter Ott; Kim Dalhoff; Bent-Adel Hansen; Fin-Stolze Larsen
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

5.  The efficacy and safety of tadalafil: an update.

Authors:  C C Carson; J Rajfer; I Eardley; S Carrier; J S Denne; D J Walker; W Shen; W H Cordell
Journal:  BJU Int       Date:  2004-06       Impact factor: 5.588

6.  Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients.

Authors:  Kuei-Chuan Lee; Ying-Ying Yang; Ying-Wen Wang; Ming-Chih Hou; Fa-Yauh Lee; Han-Chieh Lin; Shou-Dong Lee
Journal:  Hepatol Res       Date:  2008-07-04       Impact factor: 4.288
  6 in total
  2 in total

Review 1.  Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 2.  Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.

Authors:  Seong Hee Kang; Moon Young Kim; Soon Koo Baik
Journal:  Hepatol Int       Date:  2017-07-11       Impact factor: 6.047
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.